The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients

• Status: Unknown status
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to explore and identify the effects of acetylcysteine, a common mucolytic with anti-oxidant property, on alleviating the damage caused by increased oxidative stress in hemodialysis patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Far Eastern Memorial Hospital
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• On HD thrice a week at our HD unit for more than three months

• Informed consent

• The dose of EPO and iron supplement is stationary in the previous one month

• No taking acetylcysteine in previous one month

• No using vitamin E-bonded dialysis membrane

Exclusion Criteria:

• Severe liver disease (AST or ALT >40 IU/L), proven malignancy, and severe cardiovascular disease (proved by cardiac catheter or echography examination)

• Active infection or hospitalization in previous one month

• Clinically significant bleeding episode in previous one month

• Taking vitamin C, vitamin E or other known antioxidants.